Scalable TESSA® Vector Manufacture To Support AAV Gene Therapy

By A Lennon, M Fujinobu, A Dooner, L Montgomery, D Lisiecka, D Chow, W Su

Producing adeno-associated virus (AAV) vectors at a commercial scale remains one of the key challenges in gene therapy manufacturing. A novel helper system has been developed to overcome these limitations by enabling efficient, high-quality AAV production in suspension cell culture. Designed with precise regulatory features, the platform minimizes unwanted byproducts and enhances yield consistency while improving overall process safety. Its flexible design supports multiple production pathways, allowing researchers and manufacturers to adapt easily to different vector configurations and therapeutic needs.

This versatility facilitates smooth process scale-up from laboratory to large-scale bioreactors without compromising product integrity. Rigorous quality control ensures strong genome stability, purity, and infectivity, resulting in reliable performance across manufacturing campaigns. By combining scalability, efficiency, and cost-effectiveness, this next-generation approach represents a major step forward in meeting the growing demand for high-quality AAV vectors supporting the advancement of gene therapy development worldwide.